AB0 blood group type has been linked with different types of cancer. For rectal cancer, there isn’t enough data to assess whether such risk exists. We conducted a retrospective study to evaluate the association between ABO blood type and risk of susceptibility to development, progression, or protection against rectal cancer. We analyzed the medical records of 690 patients with rectal cancer from “Prof. Dr. Alexandru Trestioreanu” Oncological Institute of Bucharest during 8 years of follow-up. Data were scraped using Python. For analysis, we used the Chi-square test. The blood group count was A (287, 41.6.%) followed by 0 (250, 36.2%), B (32, 4.6%), and AB (121, 17.5%). There are no differences in the female and male subgroups regarding blood type and the lack of evidence for the null hypothesis rejection was shown using the χ2 test statistic (χ2 = 2.1, d.f. 3, p = 0.55 for males and χ2 = 2.9, d.f. 3, p = 0.4 for females). These findings are consistent with the notion that even if AB0 blood type is a risk factor for many types of cancer, there is no specific association between rectal cancer and blood group type.
Asymptomatic bacteriuria (ABU) is a common finding in everyday clinical practice. Many patients, many of them with significant comorbidities, will present, when tested, with bacterial colonization of the urine even if they have no lower urinary tract symptoms at all. Therefore, the clinician is having a dilemma: Should I prescribe antibiotics to sterilize the urine or not? This article aims to update and eventually support physicians in the difficult decision of whether to treat or not to treat patients with ABS and when.
Daniela G. Bălan,
Filip Calangiu,
Georgiana Tănase,
Raluca Tulin✉,
Sebastian Isac,
Dragos E. Georgescu,
Dorin Dragos,
Claudia Cobilinschi,
Liviu V. Chiperi,
Dorin Ionescu,
Andra E. Balcangiu-Stroescu,
Amalia L. Calinoiu,
Adina Rusu,
Ileana A. Vacaroiu View full articleAs general population tends to have increasing life expectancy, the risk associated with developing chronic kidney disease (CKD) with multiple incapacitating concequences, also increases. Method: For the present study, we registered the data from the observation files of 37 patients diagnosed with CKD undergoing treatment by chronic hemodialysis and noted the CKD associated diagnoses included in the notion of comorbidities. We monitored their statistical incidence both in the whole group and separately, in women and men using TTEST and CORREL. Results: The median age of the subjects was 55.86 (± 12.00) years. The study population mean weight was 74.90 (± 14.44) kg, with a mean weight of 69.33 kg for female subjects, and 77.92 kg for males, respectively. Diabetes was identified in 35.13% of patients, whilst heart failure was present in 16.21% of patients. Conclusions: Following the analysis of the information about the patients with CKD in the dialysis program, which we included in the study group, we observed the existence of variations that occur with age, significant correlations between age and weight and between albuminemia and weight. The most common comorbidity is high blood pressure followed by anemia.
The squamous cell carcinoma antigen is a tumor marker that is receiving more interest due to its biological properties and importance in both pathological and normal physiological processes. Numerous clinical studies have been conducted to determine the potential function of squamous cell carcinoma antigen and its isoform complexes in clinical practice. These studies have been prompted by the fact that not only squamous cell carcinoma antigen but also circulating immune complexes of it and immunoglobulin M are involved in normal physiological and pathological processes. The therapeutic use of squamous cell carcinoma antigen as a tumor marker for either squamous carcinoma diagnosis or for monitoring the response to radiation or chemotherapy, tumor recurrence, and treatment failure are supported by prior investigations. The diagnostic or prognostic utility of squamous cell carcinoma antigen is debatable, nevertheless, as these investigations provide conflicting findings. A uniform detection method, scoring system, and cutoff level must be devised to limit clinical variability between studies and to provide a more accurate and trustworthy comparison of data. Additionally, even if the effectiveness of several approaches is equivalent, only one method should be used for the dynamic monitoring of tumor marker kinetics.
